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Patient safety related to orthopaedic implants, particularly
joint arthroplasty, is a major concern due to the increasing
elderly population and the wide variety of available
devices. The safe use of medical devices, such as orthopae-
dic implants, is regulated by institutions or governmental
agencies in many countries. Nevertheless, adverse inci-
dents associated with the implantation of orthopaedic
devices in patients are reported periodically in the news
media.
Recently, a series of 47 consecutive patients with falsely
implanted total knee arthroplasties was reported in Ger-
man newspapers [1-5]. Between May 2006 and March
2007, orthopaedic surgeons in a German hospital errone-
ously implanted femoral components for total knee
replacements in a non-cemented fashion, although these
specific implants had been designed for cemented use
only [1-5]. Apparently, multiple contributing factors
accounted for these adverse events in which patients were
harmed by a combination of human failure and system
errors. Until present, 30 patients underwent a surgical
revision, four patients have been scheduled for revision
surgery, and the remaining 13 patients have not reported
any complaints [6].
The disputed US-manufactured knee prosthesis is availa-
ble in two different versions, for use with or without
cement. This specific implant was introduced at the
reported hospital in May 2006. A root cause analysis
revealed that one of the contributing factors leading to
wrong use of this implant was related to the original pack-
age labeled in English language. The labeling of the femo-
ral component packaging as "non-modular cemented"
was erroneously translated to "non-cemented" or "with-
out cement" by the responsible hospital staff [1-4]. With
respect to the German law on medical products, all
devices must be delivered with an according German
instruction [7]. In the present case, the US manufacturer
of the knee prosthesis included a German instruction
inside the package [2]. About one year later, a sticker with
the German translation of "without cement" was added to
the package labeling of the "true" cementless version. At
the time, the responsible hospital staff suddenly realized
that some femoral components designed for cemented
use had been erroneously implanted in a cementless fash-
ion [3].
Aside from this system error related to wrong language
translation and interpretation, another contributing fac-
tor which led to the wrong use of this orthopaedic device
might have been a misinformed representative by the
manufacturing company who was present in the operat-
ing room at the time of surgery. According to the hospi-
tal's spokesperson, the components for cemented use only
were sorted into the shelves designated for cementless
components despite continuing supervision by the com-
pany's representative. Apparently, this particular repre-
sentative attended knee arthroplasty procedures at this
hospital and assisted the operative surgeons in technical
issues related to this newly introduced implant [1,3].
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According to the US manufacturer, no serious adverse
events or technical problems have been reported within
15 years of distribution in Germany. No comments were
made related to the potential aspect of an individual
human failure by the company's representative [1,3].
The shocking fact that 47 consecutive patients suffered
from the same basic error implies that not only human
failure, but also system errors and lacking control mecha-
nisms may have contributed to this series of adverse
events.
As outlined by this alarming example, most adverse events
in medical or surgical procedures are typically of multifac-
torial origin. This includes organisational and structural
mismanagement which may be accentuated by unpredict-
able individual human failure [10]. A root cause analysis
of the above-mentioned case scenario should help to
improve patient safety related to the improper handling of
orthopaedic implants in the future.
Analogous to the Food and Drug Administration (FDA) in
the USA, the Federal Institute for Drugs and Medical
Devices in Germany regulates the use of any medical
device that is intended for use in the diagnosis, mitiga-
tion, treatment, or prevention of disease [7,11]. The FDA
regulations ascertain that all labeling of medical products
must be in English language [12]. The terms "label" and
"labeling" are specifically defined as "display of written,
printed, or graphic matter upon the immediate container
of any article..." and "all labels and other written, printed,
or graphic matter upon any article or any of its containers
or wrappers..." [12]. The German law regulating the use of
medical devices demands that product information, par-
ticularly safety issues, are provided in German language.
However, this regulation does not specifically demand
that labeling of packaging of medical devices must be in
German language [7]. As outlined in the present case, the
English language package labeling of an arthroplasty
implant was the basis of a wrong translation/interpreta-
tion of the label and thus led to an improper implantation
of total knees. From a human failure perspective, the dis-
tinct coating properties between the cemented and unce-
mented version of the femoral component (porous vs.
smooth surface) were neither recognized by the instru-
menting personnel, nor by the responsible surgeon at the
time of surgery [1,3,4].
Another aspect to be addressed is the role of the presence
of a health care industry representative (HCIR) in the
operating room. According to the American College of
Surgeons (ACS), industry representatives in clinical set-
tings are assigned an important role in patient safety and
quality of care by providing detailed information about
the proper use of medical devices [13]. However, the sur-
geon in charge – as the "captain of the ship" – remains
ultimately responsible for the adequate performance of
surgical procedures [13,14]. On the other hand, compa-
nies manufacturing medical devices must take adequate
steps to ensure a proper education and instruction of their
representatives. This was obviously not warranted in the
present case. With respect to the protection of patients'
rights and privacy, we also question why patients'
informed consent is not required for the presence of third
parties in the operating room, such as HCIRs.
The establishment of regional, national, or international
reporting systems and quality control registries may help
avoiding repeated identical error patterns, e.g. by early
detection of a discrepancy between type of implant and
the implanting procedure. The Swedish Hip Registry has
been established for many years now and directly influ-
enced the number and types of available hip implants by
eliminating those with poor performance [15]. Although
these consequences result from long-term data, the Nor-
wegian hip registry successfully demonstrated detection of
poor cement quality and subsequent recall at an early
stage [16].
Since the introduction of the Swedish hip registry in 1979,
revision rates for hip arthroplasty have been reduced
approximately by half, to currently 7% [15,17,18]. In con-
trast, the mean revision rate for total hip arthroplasty in
the USA is still as high as 18% [18,19]. It is conceivable
that formal registries on joint arthroplasties may help
identifying implantation-related errors at an early stage
and thus prevent further patients from undergoing inade-
quate surgical procedures.
We wish to emphasize that the particular incidence ana-
lyzed here, based on a rare event which occurred in a sin-
gle German hospital, but may reflect the "tip of the
iceberg" of an unrecognized risk for patient safety in joint
arthroplasty. This notion is exemplified by the world-wide
recall of the Interop acetabular cup by Sulzer Orthopedics
(Austin, TX) due to a manufacturing error in 2001. This
error was attributed to a modified cleaning process, which
left oily residues on the implant's porous coating [8]. Dur-
ing the time of introduction of this acetabular cup in 1997
and its worldwide recall in 2001, the device had been
implanted in about 17,500 patients. By 2005, about 2,500
patients had undergone revision surgeries due to the mal-
fabricated cup [9]. A retrospective study reported a failure
rate of 30% for the Interop shell within two to 17 months
after total hip arthroplasty [9].
The high number of adversely affected patients in this
example demonstrates that the identification and correc-
tion of manufacturing errors in joint implants may take
several months to years. Obviously, in times of a globalPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Patient Safety in Surgery 2007, 1:5 http://www.pssjournal.com/content/1/1/5
Page 3 of 3
(page number not for citation purposes)
market with worldwide product distribution, any ortho-
paedic device may be implanted in hundreds or thou-
sands of patients within a very short period of time. This
example emphasizes the need for a systematic approach
for implementation of an "early warning system" in order
to improve patient safety.
In summary, patient safety in the context of routinely and
frequently performed surgical procedures, such as total
joint replacement, needs to be improved in a systematic
fashion. In the case related to wrong translation of prod-
uct labels, the unequivocal labeling should be mandatory
for all product containers and wrappings in the language
of the country where the implant is used.
With respect to the role of HCIRs, surgical department
administrators should establish specific written policies
governing the presence of third parties in the operating
room. The surgeon remains ultimately responsible for
correct use of orthopaedic implants and must be familiar
with all specific details of instrumentation and implanta-
tion techniques. In the case where a surgeon uses an
implant for the first time, we recommend a prior on table
demonstration and training of correct implant handling
by an HCIR. Patients should furthermore be informed
about the presence of HCRIs in the operating room and
provide a written informed consent for allowing non-
medical third parties in the operating room.
The last column in patient safety with respect to orthopae-
dic implants addresses public institutions which supervise
medical products and patient concerns. With regard to
joint arthroplasty, studies have shown that formal regis-
tries can improve long-term patient safety by reducing
complication and revision rates significantly [12-15].
Such registries must be designed in a way that allows an
early identification of errors and failures, in order to avoid
repetitive errors which may consecutively affect a large
patient population.
Competing interests
The author(s) declare that they have no competing inter-
ests.
References
1. Klinikskandal: Wer hat Schuld?   [http://www.morgenpost.de/
content/2007/08/15/berlin/915886.html]
2. Anzeige gegen St. Hedwig und Hersteller   [http://
www.welt.de/berlin/article1108814/
Anzeige_gegeb_St._Hedwig_und_Hersteller_.html]
3. Senat fordert Warnsystem für Kliniken   [http://
www.tagesspiegel.de/berlin/Kliniken-Hueftgelenke;art270,2358117]
4. Knieprothesen sind kaum zu verwechseln   [ h t t p : / /
www.tagesspiegel.de/berlin/Prothesenskandal;art270,2359347]
5. OP-Skandal auch in anderen Kliniken?   [http://www.morgen
post.de/content/2007/08/18/berlin/916463.html]
6. 30 Patienten haben eine neue Knie-Prothese   [ h t t p : / /
www.morgenpost.de/content/2007/09/01/berlin/919021.html]
7. Gesetz über Medizinprodukte (Medizinproduktegesetz –
MPG)   [http://www.gesetze-im-internet.de/bundesrecht/mpg/
gesamt.pdf]
8. Dorr LD, Sirianni L, OPA-C : The risk of product liability: ortho-
pedic surgeons can be trapped.  Clin Ortho Relat Res 2003,
407:50-53.
9. Blumenfeld TJ, Bargar WL: Early aseptic loosening of a modern
acetabular component secondary to a change in manufac-
turing.  J Arthroplasty 2005, 21:689-695.
10. Amoore J, Ingram P: Quality improvement report: Learning
from adverse incidents involving medical devices.  BMJ 2002,
325:272-275.
11. Is the Product a Medical Device?   [http://www.fda.gov/cdrh/
devadvice/312.html]
12. Labeling requirements   [http://www.fda.gov/cdrh/devadvice/
33.html]
13. Guidelines for collaboration of industry and surgical organi-
zations in support of research and continuing education
[http://www.fasc.org/fellows_info/statements/st-36.html]
14. Hayes JJ: The role of industry in the implantation and follow-
up of devices: a practitioner's perspective.  Card Electrophysiol
Rev 2003, 7:58-59.
15. Herberts P, Malchau H: Long-term registration has improved
the quality of hip replacement.  Acta Orthop Scand 2000,
71:111-121.
16. Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Stein AL, Vollset SE:
The Norwegian Arthroplasty Register.  Acta Orthop Scand 2000,
71:337-353.
17. Soderman P, Malchau H, Herberts P, Zugner R, Regner H, Garellick
G: Outcome after total hip arthroplasty.  Acta Orthop Scand
2001, 72:113-119.
18. Burns AW, Bourne RB: Economics of total hip arthroplasty.
Current Orthopedics 2006, 20:203-207.
19. Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M: Prevalence of
primary and revision total hip and knee arthroplasty in the
United States from 1990 through 2002.  J Bone Joint Surg Am
2005, 87:1487-97.